Navigation Links
Vion Pharmaceuticals to Present at 20th Annual Bear Stearns Healthcare Conference
Date:9/10/2007

NEW HAVEN, Conn., Sept. 10 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced today that it would make a corporate presentation at the 20th annual Bear Stearns Healthcare Conference on Tuesday, September 11, 2007 at 4:30 p.m. Eastern Time. The conference is taking place at the Grand Hyatt Hotel in New York City and the presentation will be in Ballroom D (Morosco).

Slides from the presentation will be posted to Vion's website, http://www.vionpharm.com, at 4:30 p.m. Eastern Time on September 11, 2007.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

Th
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, ... the appointment of Debra Zack , M.D., ... of Lloyd Rowland , senior vice president, ... "Debra,s expertise in biologics clinical development and ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 PMG ... its 11th clinical research site: PMG Research of Rocky ... and operation of the clinical research department at ... PMG’s presence in eastern North Carolina. This new site ... the patients in Rocky Mount and the surrounding communities, ...
(Date:9/2/2014)... , September 2, 2014 Culot ... research and lab management services  BioData, producer ... is pleased to announce the appointment of Louis ... recently served as VP Marketing and Business Development at ... research and clinical applications. Previously, Culot worked ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3Louis Culot Appointed as BioData's CEO 2
... 4, 2011 Genesis Biopharma, Inc. (OTC Bulletin Board: ... cancer therapies, today announced that it closed private offerings ... entered into definitive agreements with accredited investors to purchase ... common stock for a purchase price of $1.00 per ...
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) ... Morgan Healthcare Conference on Monday, January 10, 2011.  The ... p.m. Eastern Time).  The session may be accessed through ... Investor Relations page.  An archived version of the presentation ...
... ST. LOUIS, Dec. 30, 2010 Sigma-Aldrich® Corporation ... has acquired all outstanding shares of Cerilliant Corporation ... analytical chemistry product portfolio and to continue to ... leading supplier of high quality reference standards and ...
Cached Biology Technology:Genesis Biopharma Raises $845,000 in Private Financings 2Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio 2Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio 3Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio 4
(Date:9/2/2014)... between our immune systems and cholera bacteria, humans may ... phages. In a new study, researchers from Tufts University, ... Health Laboratory, and elsewhere, report that phages can force ... to survive. Importantly, the study published in ... phage predation occurs during human infection. , First author ...
(Date:9/2/2014)... WASHINGTON, September 2, 2014 Best-selling author Sam Kean ... of the Megalodon, the 50-foot super shark that, despite ... long extinct. Learn all about it at http://youtu.be/KhFygIoW_MA ... True Tales of Madness, Love and the History of ... is getting the Reactions treatment in a 10-episode video ...
(Date:9/2/2014)... touch a hot oven, you rapidly pull your hand ... in sensing and responding to such painful stimuli, they ... researchers have made a surprising discovery about the role ... and have built a structural model of the molecule. ... , may help direct new strategies to treat pain ...
Breaking Biology News(10 mins):War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3
... identifying a novel compound that primes a plant,s immune system, ... Chicago may be on a path to developing disease-resistant plants. ... team that includes Tim Tschaplinski of the Department of Energy,s ... the immunity response in Arabidopsis, a small flowering plant related ...
... tumors that arise from glial (supporting) cells of the ... grow fine extensions that infiltrate normal brain tissue and, ... surrounding tissue. Therefore, it is almost impossible to remove ... radical surgical removal of the tumor would substantially improve ...
... in German . Europe,s borders have ... from other parts of the world: from the American ... on, hybridise with, parasitise and out-compete native species. They ... landscapes and impact upon agriculture, forestry and fisheries. ...
Cached Biology News:Researchers discover primer to plant defense system 2Fluorescent cancer cells to guide brain surgeons 2Will Europe at last unite to combat thousands of alien invaders? 2Will Europe at last unite to combat thousands of alien invaders? 3
... These versatile vacuum cups provide flexible ... curved, or irregular surfaces. ,PFG: Flat ... Bellows cup ,PCG: Multiple Bellows cup ... from 25 to 200 mm , ...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
UGT1A6 (D-20)...
... smallest electronic pressure controller available measuring 26 ... this unit specifically for the analytical instrumentation ... carrier gas flow control, microfluidic flow control, ... focusing, the OEM-EPC offers external pressure sensor ...
Biology Products: